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Abstract
The objective of this study was to evaluate whether levels of high mobility group box 1 (HMGB1) in granulomatosis with
polyangiitis (GPA) patients are associated with carotid atherosclerosis, related to levels of soluble receptor for advanced
glycation end-products (sRAGE) and influenced by immunosuppressive or lipid-lowering therapy. Twenty-three GPA
patients and 20 controls were evaluated for HMGB1- and sRAGE levels and for carotid atherosclerosis using ultrasound to
determine intima-media thickness (IMT). In vitro the effect of atorvastatin on the production of HMGB1 by
lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVEC) was assessed. Serum HMGB1 and
sRAGE levels did not differ between patients and controls. A negative correlation was found between sRAGE and maximum
IMT but HMGB1 and carotid IMT were not related. HMGB1 levels were reduced in GPA patients on statins and prednisolone.
In vitro, atorvastatin reduced HMGB1 levels in supernatants of activated HUVEC. In conclusion, carotid IMT is inversely
correlated with sRAGE levels but not with HMGB1 levels. Statins and prednisolone are associated with reduced serum
HMGB1 levels and atorvastatin decreases HMGB1 release by activated HUVEC in vitro, indicating an additional anti-
inflammatory effect of statins.
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Introduction
High mobility group box 1 (HMGB1) is a nuclear non-histone
DNA binding protein that upon cellular death or activation is
released into the extracellular milieu and acts as an alarmin.
Extracellular HMGB1 stimulates cytokine production, cell prolif-
eration, chemotaxis, angiogenesis, and cell differentiation through
binding to its receptors that include the receptor for advanced
glycation end-products (RAGE) and Toll-like receptors (TLR)-2,
TLR4 and TLR9 [1]. Increased levels of HMGB1 have been
found in patients with granulomatosis with polyangiitis (GPA) with
active disease, especially in patients with predominantly granulo-
matous manifestations and in patients without renal involvement
at disease onset [2–4]. Individuals with subclinical atherosclerosis
and cardiovascular (CV) events present high HMGB1 levels
whereas atorvastatin decreases serum HMGB1 in hyperlipidemia
[5,6].
RAGE is a multi-ligand surface molecule involved in the
pathogenesis of vascular diseases. Soluble RAGE (sRAGE) is a
decoy receptor for RAGE ligands and decreased sRAGE levels are
associated with CV events [7]. Patients with GPA present
increased advanced glycation end-products (AGEs) accumulation
compared to controls and this accumulation is negatively
correlated with sRAGE levels [8]. We hypothesized that serum
HMGB1 levels contribute to subclinical atherosclerosis in GPA
and that this process is influenced by sRAGE but also by treatment
with prednisolone and statins.
Materials and Methods
Patients and controls
A cross-sectional study was performed on 23 GPA patients and
20 age- and gender-matched controls (Table 1) enrolled in a
previous study to evaluate carotid atherosclerosis in GPA [9]. The
study was approved by the Medical Ethical Committee (METC) of
the University Medical Center Groningen (UMCG) and written
informed consent was obtained from patients and controls. GPA
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was classified according to the European Medicines Agency
algorithm [10]. The mean disease duration was 131.2660.2
months. Birmingham Vasculitis Activity Score (BVAS) was
recorded for all patients during admissions and out-patient visits
allowing assessment of cumulative BVAS scores from the charts.
All GPA patients were evaluated during remission (BVAS=0) to
exclude influence of disease activity. Prednisolone was used by 8
patients (34.8%) at a median of 5 mg/day (3.7–10.0 mg). Statins
were prescribed for 5 (21.7%) GPA patients. Healthy controls did
not use any medication at the time of the study. Carotid
ultrasound was performed to assess intima-media thickness
(IMT) and carotid plaques as described previously [9,11]. Overall
mean IMT (mean of IMT measurements performed on carotid
bulbus, common and internal carotid arteries) and overall
maximum IMT (average of highest IMT values found in above
mentioned segments) were used for analysis. Traditional CV risk
factors were evaluated according to established guidelines [12].
Serum HMGB1 (Shino Test, Kanagawa, Japan) and sRAGE
levels (R&D Systems, Minneapolis, USA) were measured by
enzyme-linked immunosorbent assay (ELISA).
Cell cultures
HUVEC (Lonza, Breda, The Netherlands) were cultured in
EBM-2 medium supplemented with EGM-2 MV Single Quot Kit
Supplements & Growth Factors (cat No. CC-3202, Lonza) and
used when confluent. Three groups were evaluated: (1) HUVEC
pre-incubated for 2 hours with 5 mM atorvastatin (Sigma Aldrich,
Saint Louis, USA) and treated with LPS (100 ng/ml) (Sigma
Aldrich, Saint Louis, USA), (2) HUVEC treated only with LPS,
and (3) unstimulated HUVEC. Supernatants were collected for
measuring HMGB1 and interleukin (IL)-8 at baseline, 4 hours and
24 hours. All in vitro experiments were performed twice and in
duplicate. Cell viability of HUVEC was checked with 0.2% trypan
blue dye (Invitrogen, Carlsbad, USA) on HUVEC treated with
0 mM, 0.1 mM, 1.0 mM, 5.0 mM and 10.0 mM atorvastatin;
percentages of living cells were 94%, 95%, 95%, 92% and 91%
at 36 hours, respectively. Western blot was used to measure
HMGB1 in supernatants as previously described [13] while IL-8
levels were measured by ELISA (R&D Systems, Minneapolis,
USA).
Statistical analysis
Statistical analysis was performed with SPSS 18.0 software and
graphs were built using GraphPad Prism 5. Continuous variables
are presented as mean6 SD or as median and interquartile range.
Categorical variables are presented as total number and percent-
age. Comparisons between groups were performed using chi-
square test or Fisher’s exact test and Student’s t-test or Mann-
Whitney U test as appropriate. Analysis of longitudinal data from
in vitro experiments was performed by two-way ANOVA and
Bonferroni’s test. Correlations were evaluated with Spearman’s
rank correlation coefficient. Differences were considered signifi-
cant when p,0.05.
Results
HMGB1, sRAGE and subclinical atherosclerosis
Figure 1 shows similar serum HMGB1 levels in patients and
controls whereas Figures 2A and 2B depicts similar overall mean
IMT and maximum IMT in carotid arteries in GPA and controls.
Furthermore, sRAGE levels and the prevalence of carotid plaques
did not differ between patients and controls (Table 1). In GPA
patients, no correlation was found between HMGB1 and overall
maximum IMT in carotid arteries (rho= 0.062; p=0.820).
However, sRAGE levels were negatively correlated with overall
maximum IMT in carotid arteries (rho=20.565; p=0.035). No
Table 1. Risk factors for cardiovascular disease, carotid ultrasound, HMGB1 and sRAGE levels in GPA patients and controls.
Variables GPA patients (N=23) Controls (N=20) p
Median age at study, years 55.2 (45.7–62.4) 49.8 (43.0–57.4) 0.173
Females, n (%) 9 (39.1) 9 (45.0) 0.697
Age .45 years for men and 55 years for women, n (%) 16 (69.6) 12 (60.0) 0.512
Mean total cholesterol, mmol/L 4.9960.78 4.9860.82 0.978
Mean HDL, mmol/L 1.4160.37 1.5160.33 0.359
Mean LDL, mmol/L 3.0160.79 3.2960.82 0.267
Median TGL, mmol/L 1.50 (1.00–2.00) 1.00 (1.00–2.00) 0.404
Mean systolic BP, mmHg 123.65614.55 119.24610.94 0.301
Mean diastolic BP, mmHg 70.6169.38 75.1268.07 0.120
Smoking, n(%) 2 (8.7) 1 (5.0) 0.635
Family history of premature CVD, n(%) 9 (39.1) 8 (40.0) 0.954
Median BMI, kg/m2 26.0 (24.0–28.0) 23.5 (22.0–26.5) 0.256
Previous CVD, n(%) 3 (13.0) 0 (0.0) 0.236
Carotid plaques, n (%) 7 (30.4) 3 (15.0) 0.203
Overall mean IMT, mm 0.83360.256 0.76560.133 0.357
Median overall maximum IMT, mm 0.875 (0.810–1.215) 0.880 (0.830–0.990) 0.953
HMGB1, ng/ml 2.13 (1.53–4.15) 2.42 (1.73–4.07) 0.827
sRAGE, pg/mL 1256.16559.6 1483.36399.8 0.155
Numerical data are presented as mean 6 standard deviation or as median and interquartile range; BMI: body mass index; BP: blood pressure; CVD: cardiovascular
disease; HDL: high-density lipoprotein; HMGB1: high mobility group box-1; IMT: intima-media thickness; LDL: low-density lipoprotein; n: number of individuals; sRAGE:
soluble receptor for advanced glycation end-products; TGL: triglycerides.
doi:10.1371/journal.pone.0096067.t001
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correlation was present between HMGB1 and sRAGE
(rho= 0.068; p=0.777), between overall mean carotid IMT and
cumulative BVAS (rho=20.070; p=0.805) or between overall
mean carotid IMT and time in remission since last relapse/
presentation (rho= 0.337; p=0.201). Moreover, no correlation
was found between overall maximum carotid IMT and cumulative
BVAS (rho=20.050; p=0.859) and between overall maximum
IMT and time in remission since last relapse/presentation
(rho= 0.338; p=0.200). Also, no significant difference was found
between patients with and without carotid plaques regarding
HMGB1 [1.52 (1.20–2.89) ng/ml vs. 2.48 (1.74–4.22) ng/ml;
p=0.300] and sRAGE levels (1144.666817.33 pg/ml vs.
1303.996438.86 pg/ml; p=0.574).
Impact of treatment on HMGB1 and sRAGE
Since HMGB1 and sRAGE levels did not differ between GPA
patients in remission and controls, we evaluated whether therapy
would have any influence on both biomarkers. Serum HMGB1
levels were lower in patients on statins [1.26 (1.16–1.68) ng/ml vs.
2.70 (1.75–4.76) ng/ml; p=0.014] and on prednisolone [1.49
(1.21–2.61) ng/ml vs. 2.51 (1.79–5.61) ng/ml; p=0.017] com-
pared to patients without these drugs, respectively (Figure 3A and
3B). Although not significant, we observed higher serum HMGB1
levels in 12 GPA patients without statins or prednisolone
compared with 20 controls (4.0362.00 ng/ml vs.
2.8461.58 ng/ml, p=0.073). sRAGE levels did not differ between
patients with and without statins (976.206345.64 pg/ml
vs.1326.196588.79 pg/ml; p=0.275) or prednisolone
(1366.966450.80 pg/ml vs. 1196.556619.08 pg/ml; p=0.531).
Figure 1. Serum HMGB1 levels in GPA patients and controls.
GPA patients in remission present similar median HMGB1 levels
compared to controls.
doi:10.1371/journal.pone.0096067.g001
Figure 2. Intima media thickness in common carotid arteries in
GPA and controls. GPA patients present mean IMT (2A) and
maximum IMT (2B) in common carotid arteries similar to controls.
doi:10.1371/journal.pone.0096067.g002
Figure 3. HMGB1 levels in GPA patients treated with statins or
prednisolone.median serum levels of HMGB1 were significantly lower
in GPA patients treated with statins (3A) and prednisolone (3B) when
compared to patients without these drugs.
doi:10.1371/journal.pone.0096067.g003
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HMGB1 and atorvastatin in HUVEC
To investigate the relation between statins and HMGB1, we
tested the effect of atorvastatin on HMGB1-release from LPS-
stimulated HUVEC. HMGB1 in supernatants gradually increased
in time with a peak after 24 hours of LPS stimulation and a
decrease at 48 hours (Figure 4A). Thus, we compared HMGB1
and IL-8 levels in supernatants of HUVEC pre-incubated with
atorvastatin followed by 24 hours of LPS stimulation. HUVEC
stimulated with LPS showed a significantly higher production of
HMGB1 and IL-8 than unstimulated cells. Pre-incubation with
5 mM atorvastatin prior to LPS stimulation led to significantly
lower levels of both HMGB1 and IL-8 in supernatants after
Figure 4. Effect of atorvastatin on HMGB1 and IL-8 levels in HUVEC supernatants. 4A – A time curve was built to evaluate HMGB1 release
from HUVEC upon LPS stimulation. HMGB1 intensity in supernatants increases 8 hours after stimulation and a peak is observed at 24 hours with a
decrease at 48 hours. 2B and C – HMGB1 and IL-8 levels are significantly higher at 24 hours in supernatants from HUVEC treated with LPS in
comparison to unstimulated HUVEC while pre-incubation with 5 mM atorvastatin followed by LPS stimulation lowered HMGB1 and IL-8 levels
significantly at 24 hours in HUVEC’s supernatants. Experiments were performed twice and in duplicate. Data are presented as median and range, *p,
0.01 and **p,0.001.
doi:10.1371/journal.pone.0096067.g004
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24 hours in comparison to HUVEC stimulated by LPS only
(Figures 4B and 4C).
Discussion
In this study, in GPA patients HMGB1 levels were not
correlated with overall carotid maximum IMT, whereas sRAGE
levels were negatively correlated with IMT. Furthermore, statins
or prednisolone use was associated with lower HMGB1 levels.
In previous studies, GPA patients presented higher IMT levels
in carotid arteries and an increased number of CV events
compared to controls [11,14]. Accelerated atherosclerosis in GPA
was not associated with traditional CV risk factors, rather
enhanced levels of markers of vascular inflammation and
remodeling were associated with atherosclerotic disease [11]. In
this study, we evaluated HMGB1 and sRAGE levels in GPA
patients who had been enrolled in a follow-up study to evaluate
progression of atherosclerosis [9]. Patients were in remission and a
reduction of traditional CV risk factors was achieved during
follow-up of these patients that possibly resulted in similar IMT
and similar prevalence of carotid plaques compared to controls
[9]. Also, cumulative BVAS scores and time in remission were not
related to IMT values. Moreover, proteinase 3 antineutrophil
cytoplasmic antibody (PR3-ANCA) status has been shown to have
a protective role on the risk of CV events in patients with ANCA-
associated vasculitis and most of our patients were PR3-ANCA
positive [15].
HMGB1 and sRAGE have been implicated in the pathogenesis
of atherosclerotic disease. Higher serum HMGB1 levels are a
potential marker of subclinical atherosclerosis and CV events
while lower serum sRAGE levels are associated with risk factors
for CV disease and CV events [5,7]. Thus, we evaluated the
association between both biomarkers and atherosclerotic disease in
GPA. sRAGE was associated with subclinical carotid atheroscle-
rosis whereas HMGB1 was not. We hypothesized that due to its
multifaceted nature, HMGB1 is possibly more influenced by other
factors such as therapy while sRAGE levels are more stable.
Indeed, prednisolone or statins use were associated with lower
serum HMGB1 levels in our study.
Previous studies had also shown reduction of HMGB1 levels
upon statins in an experimental model of atherosclerosis and in
humans with hyperlipidemia [6,16]. In this study, we demonstrat-
ed that statins are associated with lower serum HMGB1 levels in
GPA patients in remission while a tendency for higher serum
HMGB1 levels was observed in GPA patients in remission without
statins compared with controls. Moreover, the addition of 5 mM
atorvastatin which is within the range of atorvastatin concentra-
tion used in other in vitro studies [17–21] led to a decrease in
extracellular HMGB1 levels in activated HUVEC. These findings
indicate that endothelial cells are a possible source of extracellular
HMGB1 that could be inhibited by atorvastatin. The decrease in
IL-8 levels in supernatants of activated HUVEC by atorvastatin
was used as a comparator since it is already known that statins
inhibit mRNA expression of IL-8 in activated HUVEC [22].
Inhibition of HMGB1 release by activated HUVEC points to
another potential anti-inflammatory effect of statins on vascular
endothelium. The actual mechanism of inhibition of HMGB1
release by HUVEC (i.e. inhibition of mRNA expression or
cytoplasmic translocation of HMGB1) still needs further elucida-
tion.
HMGB1 levels were also lower in GPA patients on prednisolone
therapy. Previous studies have demonstrated that corticosteroids
can reduce extracellular release of HMGB1 by monocytes in vitro
and they can also reduce HMGB1 expression and circulating
levels in vivo [23,24]. However, these findings were not confirmed
in patients with rheumatoid arthritis [25].
In conclusion, no association was observed between subclinical
carotid atherosclerosis and HMGB1 while sRAGE was negatively
associated with carotid IMT in GPA. Statin use was associated
with lower HMGB1 levels suggesting an additional anti-inflam-
matory property of statins. As subclinical atherosclerosis was
similar between patients and controls, we suggest that develop-
ment of premature atherosclerosis in GPA patients might be
postponed by sRAGE and use of statins or prednisolone. Since our
study had a relatively low number of patients and had a cross-
sectional design, further longitudinal studies are needed to
evaluate if reduction of serum HMGB1 levels might be important
in CV risk management in GPA.
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